Skip to content

Pilot Study: VR Mind and VR Mind+ Intervention

Pilot Study: Feasibility, Usability and Safety Assessment of VR Mind and VR Mind+ Intervention

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03647605
Enrollment
10
Registered
2018-08-27
Start date
2018-09-13
Completion date
2019-01-31
Last updated
2019-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Social Phobia

Keywords

vr, virtual reality, social phobia, vret, virtual reality exposure therapy

Brief summary

The aim of the pilot study is feasibility, usability and safety assessment of VR Mind intervention. In particular the subject of assessment will be: * the length of the laboratory session utilizing virtual reality exposure (feasibility), * the ergonomics and ease of use for both patients and system operators (usability), * the frequency of side effect occurrence as a result of virtual reality exposure (ie. Vertigo) (safety). The results pilot study will be used in the designing a clinical trial aimed for testing efficacy and safety of VR Mind intervention.

Detailed description

In this study, investigators will test the software developed by Tomorrow Sp. z o. o., named VR Mind. The software utilizes the concept of virtual reality exposure therapy to treat social anxiety disorder. The pilot investigators will be tested for the feasibility, usability and safety of the system in order to obtain information useful in further designs for the clinical trial. The research consists of four laboratory sessions. The first and the last session will be dedicated to participant assessment. During the second and third session the virtual reality scenarios (2 x 10 minutes for each session) will be presented to participants. The participants will be playing a role of someone who is giving a speech (Public speaking scenario) and someone who is speaking on a phone in public (Telephoning in public scenario).

Interventions

BEHAVIORALVR Mind

Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety. The pilot study will consist of two scenarios: Public Speaking in Lecture Hall and Telephoning in Public. Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes.

Sponsors

National Center for Research and Development, Poland
CollaboratorOTHER
Tomorrow Sp. z o.o.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age: 18-50 y.o. 2. Confirmed DSM-IV-TR criteria for Social Anxiety Disorder (SAD). 3. Signing informed consent

Exclusion criteria

1. Occurrence of SAD symptoms inconsistent with DSM-IV-TR criteria and with psychiatric interview (SCID-I; Structured Clinical Interview) 2. Occurrence and/or recognition: 1. psychosis, 2. bipolar disorder, 3. mental retardation 3. Exclusion based on interview: 1. pregnancy, 2. drug addiction, 3. alcohol addiction, 4. participating in the experimental session while intoxicated 5. (current) neurological treatment of chronic disease of central nervous system, 6. epilepsy, 7. paroxysmal vertigo, 8. presence of suicidal thoughts , tendencies or attempts, 9. participant is taking drugs from benzodiazepine group, other sedatives, narcotic drugs

Design outcomes

Primary

MeasureTime frameDescription
Feasibility_1: Number of participants, who have completed 4 laboratory sessions within 2 weeks.At the end of 4th laboratory session within 2 weeksNumber of participants, who have completed 4 laboratory sessions within 2 weeks.
Feasibility_2: Number of virtual reality exposure sessions completed in predefined time.At the end of 2nd and 3th laboratory session within 2 weeksNumber of virtual reality exposure sessions completed in predefined time.
Usability_ 3: immersion, perceived reality and engagementAt the end of 2 and 3 laboratory session within 2 weeks3 items with 7-point scale, where 1 is Totally agree and 7 Totally disagree: 1. The virtual reality immersed me in all aspects (Immersion), 2. The virtual reality resembled true experiences (Reality), 3. The virtual reality was engaging (Engagement).
Safety_1: occurrence and severity of simulator sicknessDuring 2nd and 3th laboratory session within 2 weeksSimulator sickness is expected adverse effect of the VR. Hence, the Simulator Sickness Questionnaire (SSQ; Kennedy, Lane, Berbaum, Lilienthal, 1993) will be administered as a primary outcome measure to evaluate safety of the VR intervention. Total SSQ score equal to or higher than 10 will be used as a preliminary cut-off for simulator sickness (Balk et al., 2013). Individual scores will be corrected for baseline (pre-VR) symptom severity. Only items with a pre-VR - post-VR increase will contribute to a final SSQ score. All post-intervention SSQ scores \>10 will be analyzed further for its association with study drop-outs and other intervention required. The adverse effect will be classified as: * mild (no intervention required, all VR sessions completed), * moderate (any intervention needed, e.g. session termination), * severe (hospitalization required), * life-threatening / death. Any unexpected adverse effects will be recorded by a physician and classified as described above.

Other

MeasureTime frameDescription
Clinical Global ImpressionDuring 1st and 4th session within 2 weeksClinical Global Impression (Guy, 1976) - is a single item, 7 point scale used by clinicians to asses the severity of illness, where 1 is labeled as Normal, not at all ill and 7 is labeled as Among the most extremely ill patients.
Subjective Units of DistressDuring 2nd and 3th session within 2 weeksSubjective Units of Distress (SUD) SUD is a subjective measure of perceived fear in certain situation. The scale range is from 0 (Totally relaxed) to 100 (Highest distress/fear/anxiety/discomfort that you have ever felt).
Patient Global ImpressionDuring 1st and 4th session within 2 weeksPatient Global Impression - is a single item, 4 point scale used by patients to asses their impression of severity of their illness and quality of their functioning in everyday life, where 1 is labeled as Normal and 4 is labeled as Severe.
Liebowitz Social Anxiety ScaleDuring 1st and 4th session within 2 weeksLiebowitz Social Anxiety Scale (LSAS; Leibowitz, 1987) The scale is composed of 24 items, depicting various social situations. For each item, participants assess their fear (from 1 - No fear to 4 - Severe) and avoidance (from 1 - Never to 4 - Usually). LSAS has 3 scores, summing the results for particular items - fear (0-72), avoidance (0-72) and total score (0-144).
Beck Depression InventoryDuring 1st and 4th session within 2 weeks

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026